Tanabe AAI LLC, a joint venture between Tanabe Seiyaku Co Ltd and aaiPharma Inc, is developing TA-2711E, an enema formulation of Tanabe's mucosal protectant ecabet, for the potential treatment of ulcerative colitis. By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the US; this remained the case in May 2006.
|Number of pages||6|
|Journal||Current Opinion in Investigational Drugs|
|Publication status||Published - May 2007|
ASJC Scopus subject areas